Literature DB >> 31008526

Perfluorinated alkylated substances serum concentration and breast cancer risk: Evidence from a nested case-control study in the French E3N cohort.

Francesca Romana Mancini1,2, German Cano-Sancho3, Juliette Gambaretti1,2, Philippe Marchand3, Marie-Christine Boutron-Ruault1,2, Gianluca Severi1,2, Patrick Arveux1,2,4, Jean-Philippe Antignac3, Marina Kvaskoff1,2.   

Abstract

Endocrine-disrupting chemicals are proposed to increase breast cancer (BC) incidence. Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), two perfluorinated alkylated substances (PFASs), are suspected to be ubiquitously present in the blood of human population worldwide. We investigated the associations between serum concentrations of these substances and BC risk. Etude Epidémiologique auprès de femmes de l'Education Nationale is a cohort of 98,995 French women born in 1925-1950 and followed up since 1990. We sampled 194 BC cases and 194 controls from women with available blood samples. Serum concentrations of PFASs were measured by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Adjusted conditional logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). All statistical tests were two sided. While PFASs concentrations were not associated with BC risk overall, we found positively linear associations between PFOS concentrations and the risk of ER+ (3rd quartile: OR = 2.22 [CI = 1.05-4.69]; 4th quartile: OR = 2.33 [CI = 1.11-4.90]); Ptrend = 0.04) and PR+ tumors (3rd quartile: OR = 2.47 [CI = 1.07-5.65]; 4th quartile: OR = 2.76 [CI = 1.21-6.30]; Ptrend = 0.02). When considering receptor-negative tumors, only the 2nd quartile of PFOS was associated with risk (ER-: OR = 15.40 [CI = 1.84-129.19]; PR-: OR = 3.47 [CI = 1.29-9.15]). While there was no association between PFOA and receptor-positive BC risk, the 2nd quartile of PFOA was positively associated with the risk of receptor-negative tumors (ER-: OR = 7.73 [CI = 1.46-41.08]; PR-: OR = 3.44 [CI = 1.30-9.10]). PFAS circulating levels were differentially associated with BC risk. While PFOS concentration was linearly associated with receptor-positive tumors, only low concentrations of PFOS and PFOA were associated with receptor-negative tumors. Our findings highlight the importance of considering exposure to PFASs as a potential risk factor for BC.
© 2019 UICC.

Entities:  

Keywords:  E3N cohort; breast cancer; nested case-control study; perfluorooctane sulfonate (PFOS); perfluorooctanoic acid (PFOA); serum levels

Mesh:

Substances:

Year:  2019        PMID: 31008526     DOI: 10.1002/ijc.32357

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Endocrine-disrupting chemicals: implications for human health.

Authors:  Linda G Kahn; Claire Philippat; Shoji F Nakayama; Rémy Slama; Leonardo Trasande
Journal:  Lancet Diabetes Endocrinol       Date:  2020-08       Impact factor: 32.069

Review 2.  Associations between Polyfluoroalkyl Substances Exposure and Breast Cancer: A Meta-Analysis.

Authors:  Haihong Jiang; Huan Liu; Ge Liu; Jing Yu; Nana Liu; Yunqin Jin; Yongyi Bi; Hong Wang
Journal:  Toxics       Date:  2022-06-11

Review 3.  Per- and poly-fluoroalkyl substances (PFAS) and female reproductive outcomes: PFAS elimination, endocrine-mediated effects, and disease.

Authors:  Brittany P Rickard; Imran Rizvi; Suzanne E Fenton
Journal:  Toxicology       Date:  2021-11-10       Impact factor: 4.571

Review 4.  Adaptive Membrane Fluidity Modulation: A Feedback Regulated Homeostatic System Hiding in Plain Sight.

Authors:  Elzbieta Izbicka; Robert T Streeper
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 5.  Cancer Progress and Priorities: Breast Cancer.

Authors:  Serena C Houghton; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-05       Impact factor: 4.090

Review 6.  Endocrine-Disrupting Chemicals and Breast Cancer: Disparities in Exposure and Importance of Research Inclusivity.

Authors:  Ashlie Santaliz Casiano; Annah Lee; Dede Teteh; Zeynep Madak Erdogan; Lindsey Treviño
Journal:  Endocrinology       Date:  2022-05-01       Impact factor: 5.051

7.  Plasma concentration of brominated flame retardants and postmenopausal breast cancer risk: a nested case-control study in the French E3N cohort.

Authors:  Francesca Romana Mancini; German Cano-Sancho; Oceane Mohamed; Iris Cervenka; Hanane Omichessan; Philippe Marchand; Marie-Christine Boutron-Ruault; Patrick Arveux; Gianluca Severi; Jean-Philippe Antignac; Marina Kvaskoff
Journal:  Environ Health       Date:  2020-05-20       Impact factor: 5.984

Review 8.  Endocrine Disruptor Potential of Short- and Long-Chain Perfluoroalkyl Substances (PFASs)-A Synthesis of Current Knowledge with Proposal of Molecular Mechanism.

Authors:  Katarzyna Mokra
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

Review 9.  PFAS and cancer, a scoping review of the epidemiologic evidence.

Authors:  Kyle Steenland; Andrea Winquist
Journal:  Environ Res       Date:  2020-12-30       Impact factor: 6.498

10.  Serum Levels of Commonly Detected Persistent Organic Pollutants and Per- and Polyfluoroalkyl Substances (PFASs) and Mammographic Density in Postmenopausal Women.

Authors:  Eunjung Lee; April Kinninger; Giske Ursin; Chiuchen Tseng; Susan Hurley; Miaomiao Wang; Yunzhu Wang; June-Soo Park; Myrto Petreas; Dennis Deapen; Peggy Reynolds
Journal:  Int J Environ Res Public Health       Date:  2020-01-17       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.